Holen Sie sich die Stockscreener-App
2.69
2.28%
0.06
Handel nachbörslich:
2.69
Schlusskurs vom Vortag:
$2.63
Offen:
$2.63
24-Stunden-Volumen:
491.89K
Relative Volume:
0.41
Marktkapitalisierung:
$190.80M
Einnahmen:
$26.87M
Nettoeinkommen (Verlust:
$-137.06M
KGV:
-1.4096
EPS:
-1.9083
Netto-Cashflow:
$-125.25M
1W Leistung:
+25.70%
1M Leistung:
+17.21%
6M Leistung:
+69.18%
1J Leistung:
+129.91%
1-Tages-Spanne:
$2.61
$2.725
1-Wochen-Bereich:
$2.18
$2.725
52-Wochen-Spanne:
$1.01
$3.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.69 | 186.55M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Zentalis Pharmaceuticals announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
ZNTL PE Ratio & Valuation, Is ZNTL Overvalued - Intellectia AI
Sentiment Review: Is Zentalis Pharmaceuticals Inc currently under institutional pressure2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Brokers Issue Forecasts for ZNTL FY2030 Earnings - marketbeat.com
Guggenheim Reiterates Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell" - marketbeat.com
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating By Investing.com - Investing.com Canada
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating - Investing.com
Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim - MarketBeat
Oppenheimer reiterates Zentalis stock rating on ovarian cancer drug By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Zentalis stock rating, $10 target By Investing.com - Investing.com Canada
Can Zentalis Pharmaceuticals Inc expand its profit marginsWeekly Market Outlook & Real-Time Sentiment Analysis - baoquankhu1.vn
Zentalis Pharmaceuticals 2025 Annual Report: Azenosertib Development, Strategic Restructuring, and Competitive Positioning - Minichart
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis (ZNTL) centers strategy on azenosertib for Cyclin E1-positive ovarian cancer - Stock Titan
Zentalis Pharmaceuticals 10-K: $0 Revenue, $(137.1)M Net Loss - TradingView
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results - MarketBeat
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - Bitget
Zentalis Pharmaceuticals (Nasdaq: ZNTL) cuts costs, extends cash runway into 2027 - stocktitan.net
Investment Recap: Can Zentalis Pharmaceuticals Inc expand its profit margins2026 Reactions & Weekly High Potential Alerts - baoquankhu1.vn
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
Aug Intraday: Can Zentalis Pharmaceuticals Inc keep up with sector leaders2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Profit Recap: Does Zentalis Pharmaceuticals Inc have a sustainable dividendEarnings Beat & Consistent Income Trade Ideas - baoquankhu1.vn
Zentalis Pharmaceuticals Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Wells Fargo & Company - Defense World
Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday - Defense World
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Bitget
Zentalis Pharmaceuticals to Present Two Posters at the - GlobeNewswire
Tech Rally: Can Zentalis Pharmaceuticals Inc expand its profit margins - baoquankhu1.vn
Wells Fargo & Company Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat
Wells Fargo assumes coverage on Zentalis stock with $5 target By Investing.com - ca.investing.com
Triple-Negative breast and Cyclin E1 ovarian cancer data headed to AACR 2026 - stocktitan.net
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC - MarketBeat
ZNTL Earnings History & Surprises | EPS & Revenue Results | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Squadron reports 3,676,900-share stake in Zentalis (ZNTL) - Stock Titan
Aug PreEarnings: What is the implied volatility of BlackRock Municipal Income TrustQuarterly Portfolio Review & Safe Capital Growth Tips - baoquankhu1.vn
Loss Report: Is Alector Inc a strong growth stock2025 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
ZNTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Is Zentalis Pharmaceuticals Inc. likely to announce a buybackMarket Activity Recap & Trade Opportunity Analysis - mfd.ru
Rate Cut: Can Zentalis Pharmaceuticals Inc. expand its profit marginsBear Alert & Proven Capital Preservation Methods - mfd.ru
Layoff Watch: Can Zentalis Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Bitget
Aug PostEarnings: Is ASTS stock heavily shortedJuly 2025 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon - Defense World
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):